Targeting innate immune mediators in type 1 and type 2 diabetes

Marc Y. Donath; Charles A. Dinarello; Thomas Mandrup-Poulsen

doi:10.1038/s41577-019-0213-9

Targeting innate immune mediators in type 1 and type 2 diabetes

Marc Y. Donath, Charles A. Dinarello, Thomas Mandrup-Poulsen

Inflammation, Metabolism and Oxidation

62 Citations (Scopus)

Abstract

Type 1 and type 2 diabetes are characterized by chronic inflammation; both diseases involve pancreatic islet inflammation, while systemic low-grade inflammation is a feature of obesity and type 2 diabetes. Long-term activation of the innate immune system impairs insulin secretion and action, and inflammation also contributes to macrovascular and microvascular complications of diabetes. However, despite strong preclinical evidence and proof-of-principle clinical trials demonstrating that targeting inflammatory pathways can prevent cardiovascular disease and other complications in patients with diabetes, there are still no approved treatments for diabetes that target innate immune mediators. Here, we review recent advances in our understanding of the inflammatory pathogenesis of type 1 and type 2 diabetes from a translational angle and point out the critical gaps in knowledge that need to be addressed to guide drug development.

Original language	English
Journal	Nature Reviews. Immunology
Volume	19
Issue number	12
Pages (from-to)	734-746
ISSN	1474-1733
DOIs	https://doi.org/10.1038/s41577-019-0213-9
Publication status	Published - 1 Dec 2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s41577-019-0213-9

Cite this

@article{09260196ab184b55a7501e453b52eb13,

title = "Targeting innate immune mediators in type 1 and type 2 diabetes",

abstract = "Type 1 and type 2 diabetes are characterized by chronic inflammation; both diseases involve pancreatic islet inflammation, while systemic low-grade inflammation is a feature of obesity and type 2 diabetes. Long-term activation of the innate immune system impairs insulin secretion and action, and inflammation also contributes to macrovascular and microvascular complications of diabetes. However, despite strong preclinical evidence and proof-of-principle clinical trials demonstrating that targeting inflammatory pathways can prevent cardiovascular disease and other complications in patients with diabetes, there are still no approved treatments for diabetes that target innate immune mediators. Here, we review recent advances in our understanding of the inflammatory pathogenesis of type 1 and type 2 diabetes from a translational angle and point out the critical gaps in knowledge that need to be addressed to guide drug development.",

author = "Donath, {Marc Y.} and Dinarello, {Charles A.} and Thomas Mandrup-Poulsen",

year = "2019",

month = dec,

day = "1",

doi = "10.1038/s41577-019-0213-9",

language = "English",

volume = "19",

pages = "734--746",

journal = "Nature Reviews. Immunology",

issn = "1474-1733",

publisher = "nature publishing group",

number = "12",

}

TY - JOUR

T1 - Targeting innate immune mediators in type 1 and type 2 diabetes

AU - Donath, Marc Y.

AU - Dinarello, Charles A.

AU - Mandrup-Poulsen, Thomas

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Type 1 and type 2 diabetes are characterized by chronic inflammation; both diseases involve pancreatic islet inflammation, while systemic low-grade inflammation is a feature of obesity and type 2 diabetes. Long-term activation of the innate immune system impairs insulin secretion and action, and inflammation also contributes to macrovascular and microvascular complications of diabetes. However, despite strong preclinical evidence and proof-of-principle clinical trials demonstrating that targeting inflammatory pathways can prevent cardiovascular disease and other complications in patients with diabetes, there are still no approved treatments for diabetes that target innate immune mediators. Here, we review recent advances in our understanding of the inflammatory pathogenesis of type 1 and type 2 diabetes from a translational angle and point out the critical gaps in knowledge that need to be addressed to guide drug development.

AB - Type 1 and type 2 diabetes are characterized by chronic inflammation; both diseases involve pancreatic islet inflammation, while systemic low-grade inflammation is a feature of obesity and type 2 diabetes. Long-term activation of the innate immune system impairs insulin secretion and action, and inflammation also contributes to macrovascular and microvascular complications of diabetes. However, despite strong preclinical evidence and proof-of-principle clinical trials demonstrating that targeting inflammatory pathways can prevent cardiovascular disease and other complications in patients with diabetes, there are still no approved treatments for diabetes that target innate immune mediators. Here, we review recent advances in our understanding of the inflammatory pathogenesis of type 1 and type 2 diabetes from a translational angle and point out the critical gaps in knowledge that need to be addressed to guide drug development.

U2 - 10.1038/s41577-019-0213-9

DO - 10.1038/s41577-019-0213-9

M3 - Review

C2 - 31501536

SN - 1474-1733

VL - 19

SP - 734

EP - 746

JO - Nature Reviews. Immunology

JF - Nature Reviews. Immunology

IS - 12

ER -